PET and SPECT-CT Imaging Technologies

Content

• 1 Overview
  • 1.1 Statement of Report
  • 1.2 Scope of this Report
  • 1.3 Methodology
  • 1.4 Executive Summary
• 2 Overview of the Medical Imaging Market
  • 2.1 Medical Imaging Industry Market Size
  • 2.2 Medical Imaging Infrastructure
    • 2.2.1 Total Healthcare Expenditures and Demographics
    • 2.2.2 Number of Hospitals
    • 2.2.3 Number of Radiologists
    • 2.2.4 Radiologic Services
    • 2.2.5 Medical Imaging Companies
    • 2.2.6 Medical Imaging Market Drivers
    • 2.2.7 Market Restraints
    • 2.2.8 Market Segments for PET Imaging
    • 2.2.9 Key Players in the PET Imaging Segment
    • 2.2.10 Medical Imaging Sector Analysis
  • 2.3 Structure and Use of PET Imaging
    • 2.3.1 Functional Imaging versus Anatomic Imaging
    • 2.3.2 Functional Imaging Using Single-Photon Imaging (SPECT)
    • 2.3.3 PET in Clinical Use
    • 2.3.4 PET Sensitivity
    • 2.3.5 Therapeutic Uses of PET
    • 2.3.6 PET/CT
    • 2.3.7 The Future of PET in Cancer Imaging
    • 2.3.8 PET Reimbursement
  • 2.4 Radiopharmaceutical Imaging
    • 2.4.1 Cardinal Health Acquires PET Radiopharmaceutical Production Facilities
    • 2.4.2 GE Healthcare Launches New Platform for Automated Synthesis of PET Radiopharmaceuticals
    • 2.4.3 Siemens Medical PETNET Radiopharmacy
    • 2.4.4 Future Growth of PET Imaging Procedures
    • 2.4.5 Diagnostic Radiopharmaceuticals: Market Analysis and Future Prospects
    • 2.4.6 New Radiopharmaceutical Applications
• 3 PET Market
  • 3.1 Market Size
  • 3.2 Total PET and PET/CT Market Trends
    • 3.2.1 Market Segmentation and Definitions
    • 3.2.2 Overview
    • 3.2.3 Market Measurements
    • 3.2.4 Market Drivers
    • 3.2.5 Market Restraints
    • 3.2.6 Future Needs for Market Development
    • 3.2.7 Clinical Usages
  • 3.3 Total PET and PET/CT Market Forecasts
    • 3.3.1 Revenue Forecasts
    • 3.3.2 Unit Shipment Forecasts
    • 3.3.3 Procedure Forecast
    • 3.3.4 Competitive Structure
    • 3.3.5 Market Share Analysis
    • 3.3.6 Future Directions for PET
    • 3.3.7 New PET Technology Platforms
  • 3.4 SPECT Market Forecasts
  • 3.5 Stand-Alone PET Market Forecasts
    • 3.5.1 Revenue Forecasts
    • 3.5.2 Unit Shipment Forecasts
    • 3.5.3 Market Share Analysis
  • 3.6 PET/CT Market Forecasts
    • 3.6.1 PET/CT Revenue Forecasts
    • 3.6.2 PET/CT Unit Shipment Forecasts
    • 3.6.3 PET/CT Market Share Analysis
  • 3.7 Products
    • 3.7.1 Gamma Medica
    • 3.7.2 Mallinckrodt
    • 3.7.3 Naviscan PET Systems
    • 3.7.4 Siemens Medical
    • 3.7.5 TeraRecon
    • 3.7.6 Toshiba America Medical Systems
    • 3.7.7 CTI Molecular Imaging Inc
    • 3.7.8 GE Healthcare
    • 3.7.9 Philips Medical Systems
    • 3.7.10 MedImage Inc
• 4 PET/CT
  • 4.1 Strengths of CT and PET Scanning
  • 4.2 Combining CT's Strengths with PET Scanning
  • 4.3 Nuclear Medicine Safety Protocols
  • 4.4 PET Safety Protocols
    • 4.4.1 Radiation Safety
    • 4.4.2 Appropriate Shielding
    • 4.4.3 Radioactive Package Protocols
  • 4.5 Regulatory Requirements
  • 4.6 PET and SPECT Tracers
    • 4.6.1 FDG Centers
  • 4.7 PET Imaging
  • 4.8 PET and Cancer Staging
  • 4.9 PET/CT Reimbursement
• 5 Hybrid Technology: PET/CT and SPECT/CT
  • 5.1 PET/CT
  • 5.2 SPECT/CT
    • 5.2.1 Blending of Technology Platforms
    • 5.2.2 SPECT vs. PET
• 6 SPECT and SPECT/CT
  • 6.1 Single-Photon Emission Computed Tomography (SPECT)
    • 6.1.1 SPECT Imaging
    • 6.1.2 SPECT Instrumentation
    • 6.1.3 SPECT Market
  • 6.2 SPECT/CT
    • 6.2.1 Differences between PET and SPECT
  • 6.3 Potential Applications of SPECT/CT
    • 6.3.1 SPECT/CT in Cardiology
    • 6.3.2 Myocardial Perfusion Imaging
    • 6.3.3 Functional Brain Imaging
    • 6.3.4 SPECT/CT in General Nuclear Medicine
    • 6.3.5 SPECT/CT in Neurology
    • 6.3.6 Oncology Applications
  • 6.4 New Technology Platforms: SPECT
    • 6.4.1 Future Growth
• 7 Clinical PET/CT for Oncology Applications
  • 7.1 Pulmonary Nodules
  • 7.2 Non-Small-Cell Lung Cancer
  • 7.3 Melanoma
  • 7.4 Lymphoma
  • 7.5 Colorectal Cancer
  • 7.6 Head and Neck Cancer
  • 7.7 Esophageal Cancer
  • 7.8 Breast Cancer
  • 7.9 Brain Cancer
  • 7.10 Prostate Cancer
  • 7.11 Ovarian Cancer
  • 7.12 Cervical Cancer
  • 7.13 Testicular Cancer
  • 7.14 Thyroid Cancer
  • 7.15 Pancreatic Cancer
  • 7.16 Trends in Clinical Use of PET/CT
  • 7.17 Development of PET/MRI
• 8 Company Listings
  • Appendix 1. Radiopharmaceutical Diagnostic Imaging Agent Codes and PET Scan Services
• LIST OF TABLES
  • Table 2.1: U.S. Medical Imaging Market Size, 2001 to 2010
  • Table 2.2: Global Medical Imaging Market Size, 2001 to 2010
  • Table 2.3: U.S. Healthcare Expenditures, 1999 to 2010
  • Table 2.4: U.S. Health Expenditures as a Percentage of GDP, 1999 to 2010
  • Table 2.5: U.S. User Expenditures for Medical Imaging Equipment and Related Products
  • Table 2.6: Millions of Americans Over 65 Years of Age, 2000 to 2050
  • Table 2.7: Hospital Survey
  • Table 2.8: U.S. Radiological Images Taken, 1999 to 2010
  • Table 2.9: Worldwide Market Share Medical Imaging and Diagnostic Companies
  • Table 2.10: U.S. Nuclear Medicine Procedures, 2002 to 2010
  • Table 2.11: PET Radioisotopes
  • Table 3.1: Type of Imaging Offered by Facility
  • Table 3.2: PET Procedures by Type
  • Table 3.3: PET Patient Studies Performed in U.S
  • Table 3.4: Worldwide Dollar Sales of PET Imaging Systems, 2004 to 2011
  • Table 3.5: U.S. Dollar Sales of PET Imaging Systems, 2004 to 2011
  • Table 3.6: Average Selling Price for PET, U.S. and Worldwide, 2004 to 2011
  • Table 3.7: Unit Sales of PET Imaging Systems, U.S. and Worldwide, 2004 to 2011
  • Table 3.8: Installed Base of PET Imaging Systems, U.S., 2004 to 2011
  • Table 3.9: PET Procedure Volume, 2004 to 2011
  • Table 3.10: FDG Sales, 2004 to 2011
  • Table 3.11: SPECT Procedure Volume, 2004 to 2011
  • Table 3.12: U.S. SPECT Scanner Market Size and Growth, 2002 to 2010
  • Table 3.13: U.S. Stand-Alone PET Scanner Market Size and Growth, 2004 to 2011
  • Table 3.14: U.S. PET/CT Scanner Market Size and Growth, 2002 to 2010
  • Table 4.1: PET Applications Approved for Reimbursement by CMS
  • Table 5.1: SPECT and PET Hybrid Sales Percentages